Human NAD (P)H Dehydrogenase, Quinone 1 (NQO1)ELISA Kit

Code CSB-E14923h
Size 96T,5×96T,10×96T
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name
NAD(P)H dehydrogenase, quinone 1
Alternative Names
Azoreductase ELISA Kit; Cytochrome b 5 reductase ELISA Kit; DHQU ELISA Kit; DIA 4 ELISA Kit; DIA4 ELISA Kit; Diaphorase (NADH/NADPH) (cytochrome b 5 reductase) ELISA Kit; Diaphorase (NADH/NADPH) ELISA Kit; Diaphorase 4 ELISA Kit; Dioxin inducible 1 ELISA Kit; DT diaphorase ELISA Kit; DT-diaphorase ELISA Kit; DTD ELISA Kit; Menadione reductase ELISA Kit; NAD(P)H dehydrogenase [quinone] 1 ELISA Kit; NAD(P)H dehydrogenase quinone 1 ELISA Kit; NAD(P)H menadione oxidoreductase 1 dioxin inducible ELISA Kit; NAD(P)H quinone dehydrogenase 1 ELISA Kit; NAD(P)H: menadione oxidoreductase 1 dioxin inducible 1 ELISA Kit; NAD(P)H:menadione oxidoreductase 1 ELISA Kit; NAD(P)H:Quinone acceptor oxidoreductase type 1 ELISA Kit; NAD(P)H:quinone oxidoreductase 1 ELISA Kit; NAD(P)H:quinone oxireductase ELISA Kit; NMOR 1 ELISA Kit; NMOR I ELISA Kit; NMOR1 ELISA Kit; NMORI ELISA Kit; NQO 1 ELISA Kit; NQO1 ELISA Kit; NQO1_HUMAN ELISA Kit; Phylloquinone reductase ELISA Kit; QR 1 ELISA Kit; QR1 ELISA Kit; Quinone reductase 1 ELISA Kit
Uniprot No.
Homo sapiens (Human)
Sample Types
serum, plasma, tissue homogenates, cell lysates
Detection Range
39 pg/mL-2500 pg/mL
9.75 pg/mL
Assay Time
Sample Volume
Detection Wavelength
450 nm
Research Area
Assay Principle
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
To assess the linearity of the assay, samples were spiked with high concentrations of human NQO1 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
1:1Average %97
Range %89-101
1:2Average %89
Range %91-94
1:4Average %90
Range %82-94
1:8Average %94
Range %84-99
The recovery of human NQO1 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 9284-95
EDTA plasma (n=4)9991-103
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
25002.633 2.551 2.592 2.450
12502.093 1.976 2.035 1.893
6251.398 1.345 1.372 1.230
3120.733 0.747 0.740 0.598
1560.456 0.494 0.475 0.333
780.278 0.292 0.285 0.143
390.221 0.217 0.219 0.077
00.144 0.140 0.142
and FAQs
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx

This Human NQO1 ELISA Kit was designed for the quantitative measurement of Human NQO1 protein in serum, plasma, tissue homogenates, cell lysates. It is a Sandwich ELISA kit, its detection range is 39 pg/mL-2500 pg/mL and the sensitivity is 9.75 pg/mL.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

(From Uniprot)
The enzyme apparently serves as a quinone reductase in connection with conjugation reactions of hydroquinons involved in detoxification pathways as well as in biosynthetic processes such as the vitamin K-dependent gamma-carboxylation of glutamate residues in prothrombin synthesis.
Gene References into Functions
  1. functional perturbation analyses at cancer-associated P187 and K240 sites of the multifunctional NADP(H):quinone oxidoreductase 1 PMID: 30009918
  2. NQO1 is a FAD-dependent, two-domain multifunctional stress protein acting as a Phase II enzyme, activating cancer pro-drugs and stabilizing p53 and p73a oncosuppressors.tructural protein:protein interaction studies reveal that the cancer-associated polymorphism does not abolish the interaction with p73alpha, indicating that oncosuppressor destabilization largely mirrors the low intracellular stability of p.P187S. PMID: 28291250
  3. Inflammation, oxidative stress, and higher expression levels of Nrf2 and NQO1 proteins in the airways of women chronically exposed to biomass fuel smoke. PMID: 29363060
  4. NQO1 directly binds to the oxygen-dependent domain of HIF-1alpha and inhibits the proteasome-mediated degradation of HIF-1alpha by preventing PHDs from interacting with HIF-1alpha. PMID: 27966538
  5. Our genetic susceptibility study suggests that the NQO1 wild homozygous is likely to be the susceptible genotype. It means that low dose exposure to benzene (concentration under 0.6 mg/m3) can still cause health hazards to workers, and those workers with NQO1 wild homozygous genotypes were more susceptible than others. PMID: 29116991
  6. Although the NQO1 rs1800566 variant may not have an effect on risk of pre-eclampsia (PE) in Chinese Han women, further studies of other loci are necessary to clarify the exact role of NQO1 in the pathogenesis of PE. PMID: 29153688
  7. results obtained here support a previously unrecognized molecular link between polycystic ovary syndrome and endometrial cancer involving NQO1. PMID: 28748640
  8. In human colonic epithelial cells, significant upregulation of NAD(P)H dehydrogenase [quinone] 1 (up to threefold) and thioredoxin reductase 1 (up to twofold) by 10muM sulforaphane (from broccoli), 5muM carnosol (rosemary), and 20muM cinnamaldehyde (cinnamon) was observed. PMID: 28688915
  9. Hydrogen sulfide attenuates vascular smooth muscle cell calcification in vitro via the KEAP1-NRF2 redox sensing/stress response system by enhancing NQO1 expression. PMID: 28865326
  10. the NRF2 target NAD(P)H:quinone oxidoreductase 1 (NQO1) was investigated as a readout parameter for NRF2 activity in monocytes of chronic kidney disease patients (n = 63) compared to those of healthy controls. PMID: 28785379
  11. NQO1 is a potential drug target for host directed therapy for tuberculosis. PMID: 27297123
  12. These results indicate that dual-negative expression of Nrf2 and NQO1 is predictive of a better prognosis in NSCLC patients. PMID: 28501854
  13. the NQO1 Pro187Ser or SULT1A1 Arg213His polymorphism combination with smoking significantly confer susceptibility to BC. [META-ANALYSIS] PMID: 28589969
  14. Docosahexaenoic acid (DHA) activates Nrf2, possibly through modification of critical Keap1 cysteine 288 residue and PKCdelta-mediated phosphorylation of Nrf2, leading to upregulation of HO-1 and NQO1 expression. PMID: 28604588
  15. the upregulation of Cav1 contributed to the DHA-mediated p53 activation and the downregulation of the redox enzyme, NAD(P)H:quinone oxidoreductase 1 (NQO1), which have been reported to contribute to the activation of the cell death pathway. PMID: 28498397
  16. NQO1 may act as a redox-dependent switch where the protein responds to the NAD(P)+/NAD(P)H redox environment by altering its structure promoting the binding or dissociation of NQO1 with target macromolecules PMID: 29298345
  17. Taken together, we proposed that NQO1 could potentiate NSCLC cell proliferation by enhancing cellular glycometabolism, and HKII is a key mediator of this mechanism. PMID: 29291405
  18. The higher incidence of NQO1 mutants among bronchopulmonary dysplasia (BPD) neonates as well as the presence of the mutant allele in all neonates with <= 1,000 g who developed BPD provided the first evidence for a possible pathogenetic role of the C(609)T polymorphism in BPD susceptibility due to the reduction or loss of NQO1 enzymatic activity. PMID: 26683602
  19. Activity of the enzyme NQO1 does not appear to be developmentally regulated, with levels of hepatic activity as high in neonates and children as they are in adults. Obesity may increase hepatic NQO1 activity in children. PMID: 26856346
  20. Novel RNA-binding activity of NQO1 promotes SERPINA1 mRNA translation. PMID: 27515817
  21. NQO1 overexpression correlated to tumor size, venous infiltration and late pTNM stage of hepatocellular carcinoma. NQO1 overexpression was also related to low disease-free survival and 5-year survival rates. PMID: 28964792
  22. Results from reverse transcription polymerase chain reaction and promoter assays reveal that HX-1171 increased the expression of NQO1 and HMOX1, encoding antioxidant-related enzymes, in A549 human lung epithelial cells. PMID: 28300285
  23. Results show that H80R causes a population shift in the conformational ensemble of apo-P187S, remodelling the structure and dynamics of the FAD-binding site and reducing the energetic penalization arising from the equilibrium between apo- and holo-states. PMID: 28771686
  24. The C609T polymorphism within NQO1 is independently associated with CAD in women, but no association was observed in whole study population or in men. PMID: 26690082
  25. This study suggests that HNC samples should be screened for NQO1 expression to identify patients that will likely benefit from combined therapy with beta-lap and IR. PMID: 27196777
  26. The results indicate that NQO1*2 genotype may increase susceptibility to DN in north Indian subjects with T2DM. PMID: 27078674
  27. Thus, our findings indicated that NQO1 could stabilize Herp protein expression via indirect regulation of synoviolin. PMID: 27084451
  28. NQO1 and GCLC were both functionally sufficient to autonomously confer a tamoxifen-resistant metabolic phenotype, characterized by i) increased mitochondrial biogenesis, ii) increased ATP production and iii) reduced glutathione levels. PMID: 28411284
  29. NQO1 induces hepatocellular carcinoma cell apoptosis and proliferation inhibition through the AMPK/PGC-1alpha pathway. PMID: 28191864
  30. the expression of NRF2, KEAP1, NQO-1 and HO-1 are increased significantly in advanced laryngeal squamous cell carcinoma, compared with the adjacent normal mucosa. Remarkable relevance exists between high expression of KEAP1, NQO-1, HO-1 and nuclear NRF2. their expression levels were independent of age, tumor stage (clinical stage III and IV), tumor size and lymph node metastasis. PMID: 27840932
  31. (i) melatonin counteracted UVR-induced alterations in the ATP synthesis and reduced free radical formation; (ii) melatonin induced the translocation of Nrf2 transcription factor from the cytosol into the nucleus resulting in, (iii) melatonin enhanced gene expression of phase-2 antioxidative enzymes including gamma-glutamylcysteine synthetase (gamma-GCS), heme oxygenase-1 (HO-1), and NADPH: quinone dehydrogenase-1 (NQO1... PMID: 27117941
  32. Coptisine exerted its antioxidant activity against AAPH-induced toxicity involving in activating Akt and JNK/Nrf2/NQO1 pathway. PMID: 27903425
  33. These results do not support the view that the C609T polymorphism has a role in the pathogenesis of Myelodysplastic Syndrome. PMID: 27453274
  34. significant structural and functional changes incurred by NQO1 antioxidant protein as a result of alteration in its nucleotide, are reported. PMID: 27349566
  35. Study provides a comprehensive picture of the structural and dynamic consequences of NQO1 polymorphisms, linking changes in protein dynamics with impaired NQO1 function and FAD binding, particularly for p.P187S, leading to increased cancer susceptibility. PMID: 26838129
  36. Polymorphism of the NQO1 Gene is associated with Breast Cancer. PMID: 27039751
  37. patients who carry the wild type genotype or only one polymorphism for either NQO1 or GSTP1 gene have possibly a better clinical outcome after the natalizumab therapy. PMID: 27993870
  38. The association of colorectal adenomas with the rs6983267 variant at 8q24 was considered as 'highly credible', the 'less credible' associations were identified with a further four variants of four independent genes: MTHFR c.677C>T p.A222V(rs1801133), TP53 c.215C>G p.R72P (rs1042522), NQO1 c.559C>T p.P187S (rs1800566), and NAT1 alleles imputed as fast acetylator genotypes. [meta-analysis] PMID: 26451011
  39. Results show that NQO1 is up-regulated in non-small cell lung neoplasm which correlates with poor survival. PMID: 26553038
  40. Meta-analysis. our results showed that NQO1 C609T polymorphism increases the risk of Alzheimer disease in Chinese populations. PMID: 25562627
  41. The present study revealed that NQO1 CT, TT and CT+TT genotypes may be associated with clinical outcome and risk of developing NSCLC in the Indian population. PMID: 26625776
  42. Flavin reductase and calreticulin play key roles in the development of pemetrexed-associated resistance in lung adenocarcinoma cells. PMID: 26452990
  43. NQO1 was significantly increased in all of the diseased livers including peri-hepatocellular carcinoma tissues. PMID: 26459724
  44. NQO1 single nucleotide polymorphism rs1800566 involved in the ornithine decarboxylase pathway can be a genetic susceptibility factor for gastric cancer. PMID: 25079701
  45. NQO1 overexpression was a main determinant for a potential chemotherapy resistance or an increased sensitivity to quinone-bearing compounds. PMID: 26687450
  46. mercury increases oxidative stress (increased HO1 and NQO1 mRNA levels) and alters the cytoskeleton in the human endometrial Ishikawa cell line and to a lesser extent, in the "less-differentiated" human endometrial Hec-1b cells PMID: 26600472
  47. NQO1 gene polymorphisms influence stable warfarin doses in Korean patients PMID: 26257249
  48. The present results demonstrate that exacerbated cisplatin-induced nephrotoxicity under the NQO1-knockout condition was accompanied by the reduced expression of MRN complex proteins, ATM, PARP1, and Sirt1. PMID: 26723870
  49. Its genotype in cervical cell samples may be associated with more severe precancerous lesions of the cervix in a Japanese population. PMID: 25697264
  50. NQO1 Stabilizes p53 in Response to Oncogene-Induced Senescence. PMID: 26078718

Show More

Hide All

Subcellular Location
Protein Families
NAD(P)H dehydrogenase (quinone) family
Database Links

HGNC: 2874

OMIM: 125860

KEGG: hsa:1728

STRING: 9606.ENSP00000319788

UniGene: Hs.406515

Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
7505 Fannin St., Ste 610, Room 322 (CUBIO Innovation Center), Houston, TX 77054, USA
Join Us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2023 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1